Purpose: To evaluate the effect of different enucleation techniques on operation time, enucleation efficacy and postoperative results. Materials and Methods: 178 HoLEP cases performed by two senior surgeons were evaluated retrospectively. All patients were evaluated for age, IPSS, preoperative PSA, prostate size, maximum flow rate (Qmax) postvoid residual volume (PVR), enucleation time, morcellation time, enucleated tissue weight, enucleation ratio (enucleated tissue weight/prostate volume) and enucleation time efficacy (enucleated weight/enucleation time). Patients were categorized into three groups according to performed enucleation techniques; Retrograde Low Tension (RLT) two-lobe, traditional three-lobe, and en bloc techniques. IPSS, Qmax, PVR and transient urine leakage (TUL) were evaluated during postoperative follow up. All preoperative, intraoperative and postoperative results were compared between 3 groups. Results: Mean age was 70.52 (52-85) years. Baseline data were comparable between groups. Enucleation time was significantly shorter in RLT two-lobe (median; 50, 60 and 60 min; RLT two-lobe, traditional three-lobe, and en bloc HoLEP techniques, respectively. (P = .031). Morcellation time was comparable between groups (P = .532). No significant difference was observed between morcellated prostate weights (P = .916) Significant improvements in IPSS, Qmax, and PVR were noted in all groups (P <.001). TUL was significantly increased in en bloc technique (P = .034). Postoperative stricture rates were similar between groups. (P = .769) Conclusion: Shorter enucleation time was observed in the RLT HoLEP technique and increased TUL rate was observed in the en bloc technique.
Background: PSMA PET/CT has previously shown superior performance in nodal staging of prostate cancer (PCa) and may be used to reduce the number of unnecessary PLND procedures. This study aims to assess the performance of PSMA PET/CT in nodal staging of intermediate‐risk prostate cancer and to evaluate the effect of PLND on oncological outcomes of intermediate‐risk prostate cancer patients with a negative PSMA PET/CT.Methods: A total of 308 patients with intermediate‐risk PCa who underwent PSMA PET/CT for nodal staging between January 2014 and July 2024 were included in the study. Patients who underwent PLND had higher PSA and higher rates of PIRADS‐5 and biopsy grade‐group 3 disease. A 1:1 propensity score matching was performed to eliminate patient characteristics differences between groups and 140 patients were included in the final analysis. PSA persistence rates ( ≥ 0.1 ng/dL) and biochemical recurrence (BCR; ≥ 0.2 ng/dL) rates after RP were recorded. Kaplan‐Meier curves were constructed to evaluate oncological outcomes. Log‐rank test was utilized to compare oncological outcomes in patients with and without PLND.Results: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PSMA PET/CT on nodal staging were 53.3%, 95%, 47.1%, and 96.1%, respectively. The NPV of PSMA PET/CT in patients with biopsy GG3 disease (96.3%) was similar to those with biopsy GG2 disease (95.6%). The median follow‐up after propensity score matching was 20.7 months. The 24‐month BCR‐free survival rates were 83.7% and 86.9% in the PLND‐RP group and RP‐only groups, respectively (p = 0.078).Conclusions: NPV of PSMA PET/CT in determining LNI was remarkable in patients with intermediate‐risk PCa and PLND was found to have no impact on oncological outcomes. Therefore PLND may be omitted to decrease surgery‐related complications in patients with intermediate‐risk PCa a negative PSMA PET/CT for nodal staging.